Amylyx Pharmaceuticals
Market cap $3.54B 128.6M shares (10-Q, Oct 26, 2026) × $27.52 close Nov 17, 2026
Most recent annual filing: 2026-03-03
- avexitide PBH NDA filingby end of 2026avexitide PBH NDA filing, by end of 2026, material
- AMX0318 IND filing2027AMX0318 IND filing, 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
sodium phenylbutyrate and taurursodiol
AMX0035AMX0114
AMX0318
Technology platforms
Second Gubra Collaboration · Gubra
Research collaboration with Gubra A/S to identify potential development candidates for a rare endocrine disease of high unmet need; no specific candidate code disclosed.
Discontinued (1)
- AMX0035 — Progressive Supranuclear Palsy · discontinued after discontinuation of AMX0035 for PSP
Capital (as filed)
- Cash
- $240M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $528M Sep 30, 2026
- Operating cash flow
- −$33.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $768M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-08-20 424B5 · Priced offering 14.1M shares · at $35.50 · $500M gross · 8.0% below the prior close ($38.60, Aug 19, 2026)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-17 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Fine Print Holds Up 🔒 Paid
- 2026-11-06 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Factory Gets a Name 🔒 Paid
- 2026-08-20 UPDATE: Amylyx Pharmaceuticals (AMLX) - The $500 Million Vote of Confidence 🔒 Paid
- 2026-08-19 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Coin Landed Heads 🔒 Paid
- 2026-08-17 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Alarm Goes Off Tomorrow 🔒 Paid
- 2026-08-07 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Binary Has a Date 🔒 Paid
- 2026-05-08 UPDATE: Amylyx Pharmaceuticals (AMLX) — The Quiet Tells Before the Binary 🔒 Paid
- 2026-03-28 UPDATE: Amylyx Pharmaceuticals (AMLX) - The Clock Starts Now 🔒 Paid
- 2026-03-11 Amylyx Pharmacueticals (AMLX) - Scientific Deep Dive for Avexitide and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on Amylyx Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-11 Watch Amylyx Pharmacueticals (AMLX) - Scientific Deep Dive for Avexitide and Pipeline Products Avexitide's mechanistically sound GLP-1 antagonism in PBH is compelling, but small Phase 2 data and legal overhang warrant watching rather than buying ahead of the Q3 2026 Phase 3 readout.
- 2026-03-28 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Clock Starts Now LUCIDITY enrollment completion removes execution risk and locks in the Q3 2026 timeline, but the thesis remains a watch-list binary event play with no change to stance.
- 2026-05-08 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) — The Quiet Tells Before the Binary Legal overhang largely lifting, EAP launch signals management confidence, and balance sheet intact, but the Q3 binary still dominates and sizing should reflect a potential 50% downside on a miss.
- 2026-08-07 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Binary Has a Date LUCIDITY topline is now dated for late August/early September with all execution risk retired, but the stock's +59% run has pulled forward much of the upside, making the risk/reward closer to a fair coin flip than the original asymmetric setup.
- 2026-08-17 Watch UPDATE: Amylyx Pharmaceuticals (AMLX) - The Alarm Goes Off Tomorrow LUCIDITY topline drops at 8:00 a.m. ET tomorrow; the -11.4% pre-event drawdown modestly improves entry math but the binary distribution is unchanged and positioning should reflect a sub-24-hour coin flip.
- 2026-08-19 Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The Coin Landed Heads LUCIDITY hit its primary endpoint with a 55% placebo-adjusted reduction (p=0.000003) and all secondaries cleared, retiring clinical risk; remaining risk is commercial and manufacturing, making this a speculative buy at the post-data price.
- 2026-08-20 Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The $500 Million Vote of Confidence The offering upsized to $500M and priced above the prior close, signaling oversubscription and institutional demand; the war chest now exceeds $720M, but CMO agreements are not yet signed and the easy money is behind us.
- 2026-11-06 Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The Factory Gets a Name Bachem supply agreement signed and Polypeptide at term sheet with $30M committed partially retires the CMC risk I graded High; stock trades 22% below deal price, improving the asymmetry versus August.
- 2026-11-17 Speculative buy speculative UPDATE: Amylyx Pharmaceuticals (AMLX) - The Fine Print Holds Up Full LUCIDITY data at ObesityWeek confirms the topline with 0.55 vs 1.24 events/week and all prespecified secondaries hit; an 8% post-data dip on confirmatory results may be worth a look for those waiting on the full dataset.
- Long call · opened Aug 19, 2026 at $38.60 · -28.7% vs XBI -14.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Topline data readout for the Phase 3 LUCIDITY clinical trial of avexitide in PBH is on track and anticipated in late August or early September 2026.”
matched to Avexitide · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (36)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 15, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 14, 2026ReleaseAmylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting→ BD updateThe full LUCIDITY dataset landed at ObesityWeek and it's even cleaner than the topline suggested: avexitide cut hypoglycemic events from 1.24 to 0.55 per week versus placebo, all four secondary endpoints hit with p-values down to 0.0000032 — and the stock is somehow still trading 22% below the August offering price.
- Nov 5, 2026ReleaseAmylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings bring the two things the thesis needed most: Amylyx has signed a definitive manufacturing deal with Bachem Americas and a binding term sheet with Polypeptide Group AG (with a $30M upfront capacity reservation), closing the CMC risk I'd been flagging as the last major overhang — and the stock has quietly given back 30% of its post-LUCIDITY gains, setting up an interesting entry point ahead of the ObesityWeek data presentation on November 15.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseAmylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
- Nov 3, 2026ReleaseAmylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
- Nov 2, 2026ReleaseAmylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
- Oct 6, 2026ReleaseAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingBD extracted 1 program update from this document → AMLX pipeline
- Sep 23, 2026ReleaseAmylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
- Sep 8, 2026ReleaseAmylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
- Sep 8, 20268-KCurrent report: material agreement
- Aug 20, 20268-KCurrent report: material agreement
- Aug 20, 2026424B5Prospectus supplement (offering)
- Aug 19, 2026ReleaseAmylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
- Aug 18, 2026ReleaseAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
- Aug 18, 2026ReleaseAmylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
- Aug 18, 20268-KCurrent report: other events · EX-99.1BD extracted 2 program updates from this document → AMLX pipeline
- Aug 18, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Aug 18, 2026424B5Prospectus supplement (offering)
- Aug 17, 2026ReleaseAmylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026BD extracted 1 program update from this document → AMLX pipeline
- Aug 6, 2026ReleaseAmylyx Pharmaceuticals Reports Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → AMLX pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly reportBD extracted 1 program update from this document → AMLX pipeline
- Aug 3, 2026ReleaseAmylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
- Jun 23, 2026ReleaseAmylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026BD extracted 1 program update from this document → AMLX pipeline
- Jun 8, 2026ReleaseAmylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
- Jun 4, 20268-KCurrent report: shareholder vote
- May 15, 2026ReleaseAmylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 23, 2026DEFA14AProxy soliciting material
- Apr 23, 2026DEF 14AProxy statement
- Mar 24, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 3, 2026S-3ASRAutomatic shelf registration
- Mar 3, 20268-KCurrent report: results of operations · EX-99.1
- Mar 3, 202610-KAnnual report
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the release of Nov 14, 2026
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the release of Nov 14, 2026
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 23, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment
- Mar 3, 2026S-8Employee plan registration